A Number of Marketed Dihydropyridine Calcium Channel Blockers Have Mineralocorticoid Receptor Antagonist Activity

No abstract is available for this paper.

• Publication year

  2008

• Venue

  HYPERTENSION

• Publication date

  2008-03-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1161/HYPERTENSIONAHA.107.103580PMID 18250364
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Comparison of Antihypertensive Effect and Pharmacokinetics of Conventional and Extended Release Felodipine Tablets in Patients with Arterial Hypertension

  2012cited by this paper
• A structural and in vitro characterization of asoprisnil: a selective progesterone receptor modulator.

  2007cited by this paper
• Pretreatment with eplerenone reduces stroke volume in mouse middle cerebral artery occlusion model.

  2007cited by this paper
• Dihydropyridines Inhibit Acetylcholine-Induced Hyperpolarization in Cochlear Artery via Blockade of Intermediate-Conductance Calcium-Activated Potassium Channels

  2007cited by this paper
• A Widely Used Retinoic Acid Receptor Antagonist Induces Peroxisome Proliferator-Activated Receptor-γ Activity

  2007cited by this paper
• Novel procedure for modeling ligand/receptor induced fit effects.

  2006cited by this paper
• Detecting and treating microvascular ischemia after subarachnoid hemorrhage

  2006cited by this paper
• A Ligand-mediated Hydrogen Bond Network Required for the Activation of the Mineralocorticoid Receptor*[boxs]

  2005cited by this paper
• Structural and biochemical mechanisms for the specificity of hormone binding and coactivator assembly by mineralocorticoid receptor.

  2005cited by this paper
• ACE inhibitors and angiotensin II receptor antagonists.

  2005cited by this paper
• Molecular mechanisms of mineralocorticoid receptor antagonism by eplerenone.

  2005cited by this paper
• The ligand-dependent interaction of mineralocorticoid receptor with coactivator and corepressor peptides suggests multiple activation mechanisms.

  2005cited by this paper
• A traditional herbal medicine enhances bilirubin clearance by activating the nuclear receptor CAR.

  2004cited by this paper
• Angiotensin Type 1 Receptor Blockers Induce Peroxisome Proliferator–Activated Receptor-γ Activity

  2004cited by this paper
• Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension.

  2004cited by this paper
• Expression of ENaC and serum- and glucocorticoid-induced kinase 1 in the rat intestinal epithelium.

  2004cited by this paper
• Distribution of nimodipine in brain following intranasal administration in rats.

  2004cited by this paper
• Formulation Dependent Pharmacokinetics—Does the Dosage Form Matter for Nifedipine?

  2004cited by this paper
• Dihydropyridine calcium channel blockers: basic pharmacological similarities but fundamental therapeutic differences.

  2004cited by this paper
• Angiotensin Type 1 Receptor Blockers Induce Peroxisome Proliferator–Activated Receptor-γ Activity

  2004cited by this paper
• The Three-dimensional Structures of Antagonistic and Agonistic Forms of the Glucocorticoid Receptor Ligand-binding Domain

  2003cited by this paper
• Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials

  2003cited by this paper
• Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients.

  2003cited by this paper
• The Three-dimensional Structures of Antagonistic and Agonistic Forms of the Glucocorticoid Receptor Ligand-binding Domain RU-486 INDUCES A TRANSCONFORMATION THAT LEADS TO ACTIVE ANTAGONISM*

  2003cited by this paper
• Nimodipine: Drug pharmacokinetics and plasma adenosine levels in patients affected by cerebral ischemia

  2002cited by this paper
• The hypolipidemic natural product guggulsterone acts as an antagonist of the bile acid receptor.

  2002cited by this paper
• Pathophysiological effects of aldosterone in cardiovascular tissues.

  2001cited by this paper
• Combination Calcium Channel Blocker Therapy in the Treatment of Hypertension

  2001cited by this paper
• Early aldosterone effect in distal colon by transcriptional regulation of ENaC subunits.

  2000cited by this paper
• Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy.

  2000cited by this paper
• Phosphorylation of caldesmon by ERK MAP kinases in smooth muscle.

  2000cited by this paper
• Amlodipine lowers blood pressure without affecting cerebral blood flow as measured by single photon emission computed tomography in elderly hypertensive subjects.

  1999cited by this paper
• Synthesis, Calcium Channel Antagonist Activity, and Anticonvulsant Activity of 3‐Ethyl 5‐Methyl 1,4‐Dihydro‐2‐[(2‐hydroxyethoxy)methyl]‐6‐methyl‐4‐(2,3‐dichlorophenyl)‐3,5‐pyridinedicarboxylate Coupled to a 1‐Methyl‐1,4‐dihydropyridyl‐3‐carbonyl Chemical Delivery System

  1999cited by this paper
• The action of calcium channel blockers on recombinant L‐type calcium channel α1‐subunits

  1998cited by this paper
• Felodipine inhibits free-radical production by cytokines and glucose in human smooth muscle cells.

  1998cited by this paper
• Combination drug therapy in hypertension: a rational approach for the pharmacist.

  1998cited by this paper
• Brain pharmacokinetics and in vivo receptor binding of 1,4-dihydropyridine calcium channel antagonists.

  1997cited by this paper
• Nitrendipine and mefruside in elderly hypertensives: effects on blood pressure, cardiac output, cerebral blood flow and metabolic parameters.

  1995cited by this paper
• Cerebral blood flow in patients with severe hypertension, and acute and chronic effects of felodipine

  1993cited by this paper
• Chronopharmacological Study of Nitrendipine in Healthy Subjects

  1989cited by this paper
• Differential Effects of 1,4‐Dihydropyridine Calcium Channel Blockers: Therapeutic Implications

  1987cited by this paper
• Effects of nimodipine on cerebral blood flow.

  1983cited by this paper

• Therapeutic Potential of Calcium Channel Blockers in Neuropsychiatric, Endocrine and Pain Disorders

  2025cites this paper
• A Narrative Review on Nitrate-Rich Diets as Adjuncts to Antihypertensive Therapy: Enhancing Treatment Efficacy via Oxidative Stress Modulation

  2025cites this paper
• Updates on Intrinsic Medicinal Chemistry of 1,4-dihydropyridines, Perspectives on Synthesis and Pharmacokinetics of Novel 1,4-dihydropyrimidines as Calcium Channel Blockers: Clinical Pharmacology.

  2025cites this paper
• Nimodipine reduces microglial activation in vitro as evidenced by morphological phenotype, phagocytic activity and high‐throughput RNA sequencing

  2025influential citation
• Inappropriate Prescription of Loop Diuretics for Calcium Channel Blocker-Related Peripheral Edema: Lessons from Physiology.

  2025cites this paper
• 3C. 3-Ketosteroid receptors in GtoPdb v.2025.3

  2025cites this paper
• Role of L‐type Ca2+‐channels in the vasorelaxing response to finerenone in arteries of human visceral adipose tissue

  2024cites this paper
• Clinical Management of Primary Aldosteronism: An Update

  2024influential citation
• Decoding the role of aldosterone in glycation-induced diabetic complications.

  2024cites this paper
• Novel 1,4-Dihydropyridine Derivatives as Mineralocorticoid Receptor Antagonists

  2023cites this paper
• Current Landscape of Therapeutics for the Management of Hypertension - A Review.

  2023cites this paper
• Future treatments in hypertension: Can we meet the unmet needs of patients?

  2023cites this paper
• Antihypertenseur, Activité Vasorelaxant De Rouppelinia Boivinni (Apocynaceae) Et Etude De Relation Structure-Activité Des Alcaloïdes Indoliques Isolées

  2023influential citation
• 3C. 3-Ketosteroid receptors in GtoPdb v.2023.1

  2023cites this paper
• Mineralocorticoid receptor antagonists in cardiovascular translational biology

  2023cites this paper
• Clinical effect of nonsteroidal mineralocorticoid receptor (MR) antagonists in the treatment of diabetic kidney disease: expectations as a new therapeutic strategy

  2022cites this paper
• Intratracheally Inhalable Nifedipine-Loaded Chitosan-PLGA Nanocomposites as a Promising Nanoplatform for Lung Targeting: Snowballed Protection via Regulation of TGF-β/β-Catenin Pathway in Bleomycin-Induced Pulmonary Fibrosis

  2021cites this paper
• NP-59 Adrenal Scintigraphy as an Imaging Biomarker to Predict KCNJ5 Mutation in Primary Aldosteronism Patients

  2021cites this paper
• Finerenone: First Approval

  2021influential citation
• Differential effects of eplerenone versus amlodipine on muscle metaboreflex function in hypertensive humans

  2021cites this paper
• Aldosteronismo primário. Revisão do estado da arte do JACC

  2020cites this paper
• The expanding class of mineralocorticoid receptor modulators: New ligands for kidney, cardiac, vascular, systemic and behavioral selective actions.

  2020cites this paper
• Felodipine in Treatment of Arterial Hypertension and Ischemic Heart Disease

  2020cites this paper
• Primary aldosteronism in elderly, old, and very old patients

  2020cites this paper
• Mineralocorticoid Receptor Blockers: Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonists

  2020cites this paper
• Primary Aldosteronism

  2020cites this paper
• New drug targets for hypertension: A literature review.

  2020cites this paper
• Primary Aldosteronism: JACC State-of-the-Art Review.

  2019cites this paper
• PENENTUAN LAJU ALIR SALIVA PADA PASIEN GERIATRI SEBAGAI PERTIMBANGAN MANAJEMEN KOMPREHENSIF PADA STOMATITIS HERPETIKA

  2019cites this paper
• Mineralocorticoid Receptor Antagonists.

  2019cites this paper
• Calcium Channel Blockers

  2019cites this paper
• Identification of Morpholino-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-ones as Nonsteroidal Mineralocorticoid Antagonists.

  2018cites this paper
• Calcium Ion Channels: Roles in Infection and Sepsis Mechanisms of Calcium Channel Blocker Benefits in Immunocompromised Patients at Risk for Infection

  2018cites this paper
• Epidermal growth factor receptor/extracellular signal-regulated kinase pathway enhances mineralocorticoid receptor transcriptional activity through protein stabilization.

  2018cites this paper
• Cardiac hypertrophy in chronic kidney disease—role of Aldosterone and FGF23

  2018cites this paper
• Clinical roles of calcium channel blockers in ischemic heart diseases

  2017cites this paper
• A comprehensive review of an unmet public health issue: resistant hypertension

  2017cites this paper
• Renin-angiotensin system blockade: Finerenone.

  2017cites this paper
• A small molecule screening to detect potential therapeutic targets in human podocytes.

  2017cites this paper
• Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside.

  2017cites this paper
• Modulating Mineralocorticoid Receptor with Non-steroidal Antagonists. New Opportunities for the Development of Potent and Selective Ligands without Off-Target Side Effects.

  2017cites this paper
• SFE/SFHTA/AFCE consensus on primary aldosteronism, part 7: Medical treatment of primary aldosteronism.

  2016cites this paper
• AFCE consensus on primary aldosteronism , part 7 : Medical treatment of primary aldosteronism Consensus hyperaldostéronisme primaire SFE / SFHTA , groupe 7 : Traitement médical de l ’ hyperaldostéronisme primaire

  2016cites this paper
• Comparison of the effects of L-type calcium channel antagonist Amlodipine with L/N-type calcium channel antagonist Cilnidipine on blood pressure, heart rate, proteinuria and lipid profile in hypertensive patients

  2016cites this paper
• Mineralocorticoid receptor antagonists-pharmacodynamics and pharmacokinetic differences.

  2016cites this paper
• Non‐steroidal mineralocorticoid receptor antagonism for the treatment of cardiovascular and renal disease

  2016cites this paper
• Third-generation Mineralocorticoid Receptor Antagonists: Why Do We Need a Fourth?

  2016cites this paper
• Pharmacological treatment of aldosterone excess.

  2015cites this paper
• Drug Therapy of Apparent Treatment-Resistant Hypertension: Focus on Mineralocorticoid Receptor Antagonists

  2015cites this paper
• Neue Therapiekonzepte zur Herzinsuffizienz mit erhaltener Ejektionsfraktion

  2015cites this paper
• Management of hypertension and heart failure in patients with Addison's disease

  2015cites this paper
• Mineralocorticoid Receptor Antagonists and Clinical Outcomes in Primary Aldosteronism: As Good as Surgery?

  2015cites this paper
• [New therapy concepts for heart failure with preserved ejection fraction].

  2015cites this paper
• Secondary Hypertension in Pregnancy

  2015cites this paper
• New approaches in the treatment of hypertension.

  2015cites this paper
• Outcomes of drug-based and surgical treatments for primary aldosteronism.

  2015cites this paper
• Efficacy and safety of eplerenone in the management of mild to moderate arterial hypertension: systematic review and meta-analysis.

  2014cites this paper
• Comparative effects of valsartan in combination with cilnidipine or amlodipine on cardiac remodeling and diastolic dysfunction in Dahl salt-sensitive rats

  2014cites this paper
• New antihypertensive drugs under development.

  2014cites this paper
• The velocity of home blood pressure reduction in response to low-dose eplerenone combined with other antihypertensive drugs determined by exponential decay function analysis

  2014cites this paper
• Interfering with mineralocorticoid receptor activation: the past, present, and future

  2014cites this paper
• Diuretics in the treatment of hypertension. Part 2: loop diuretics and potassium-sparing agents

  2014cites this paper
• A Case of Primary Aldosteronism with Tuberculosis in which it was Difficult to Control Drug-induced Hypertension, Hypokalemia, and Side Effects Preoperatively

  2014cites this paper
• Is there a new dawn for selective mineralocorticoid receptor antagonism?

  2014cites this paper
• Efficacy and safety of eplerenone in the management of mild to moderate arterial hypertension: Systematic review and meta-analysis☆

  2014cites this paper
• Cell type specific mechanisms of mineralocorticoid receptor mediated renal injury

  2014cites this paper
• Uso de antagonistas de aldosterona para detener la progresión de la enfermedad renal: de las bases fisiológicas a la aplicación clínica

  2014cites this paper
• Are There Any New Pharmacologic Therapies on the Horizon to Better Treat Hypertension? A State-of-the-Art Paper

  2014cites this paper
• Medical Treatment of Primary Aldosteronism

  2014cites this paper
• Primary Aldosteronism: Molecular Mechanisms and Diagnosis

  2014cites this paper
• Beneficial Effects of Proanthocyanidins in the Cardiac Alterations Induced by Aldosterone in Rat Heart through Mineralocorticoid Receptor Blockade

  2014cites this paper
• Identification of (R)-6-(1-(4-cyano-3-methylphenyl)-5-cyclopentyl-4,5-dihydro-1H-pyrazol-3-yl)-2-methoxynicotinic acid, a highly potent and selective nonsteroidal mineralocorticoid receptor antagonist.

  2014cites this paper
• Comparison of agents that affect aldosterone action.

  2014cites this paper
• Spironolactone, eplerenone and the new aldosterone blockers in endocrine and primary hypertension.

  2013influential citation
• Design of multifunctional compounds for cardiovascular disease: from natural scaffolds to "classical" multitarget approach.

  2013cites this paper
• A crossover comparison of urinary albumin excretion as a new surrogate marker for cardiovascular disease among 4 types calcium channel blockers Running title: Anti-albuminuric effects among 4 types of CaCB

  2013cites this paper
• Adrenal Diagnostics: An Endocrinologist's Perspective focused on Hyperaldosteronism.

  2013cites this paper
• Efficacies of Controlling Morning Blood Pressure and Protecting the Kidneys by Treatment With Valsartan and Nifedipine CR or Valsartan and Amlodipine (MONICA Study)

  2013cites this paper
• A crossover comparison of urinary albumin excretion as a new surrogate marker for cardiovascular disease among 4 types of calcium channel blockers.

  2013cites this paper
• Strategies for managing ACTH dependent mineralocorticoid excess induced by abiraterone.

  2013cites this paper
• Prevalence and clinical characteristics of primary aldosteronism in Japanese patients with type 2 diabetes mellitus and hypertension.

  2013cites this paper
• Mineralocorticoid receptor antagonists for the treatment of hypertension and diabetic nephropathy.

  2012cites this paper
• Rationale and design of ARTS: a randomized, double‐blind study of BAY 94‐8862 in patients with chronic heart failure and mild or moderate chronic kidney disease

  2012cites this paper
• Amlodipine enhances amelioration of vascular insulin resistance, oxidative stress, and metabolic disorders by candesartan in metabolic syndrome rats.

  2012cites this paper
• Suppression of Aldosterone Synthesis and Secretion by Ca2+ Channel Antagonists

  2012cites this paper
• Key advances in antihypertensive treatment

  2012cites this paper
• Mineralocorticoid receptor-associated hypertension and its organ damage: clinical relevance for resistant hypertension.

  2012cites this paper
• 1,4-Dihydropyridines: The Multiple Personalities of a Blockbuster Drug Family

  2012cites this paper
• Spironolactone, but not eplerenone, impairs glucose tolerance in a rat model of metabolic syndrome.

  2012cites this paper
• Mechanisms of ligand specificity of the mineralocorticoid receptor.

  2012cites this paper
• Structural determinants of ligand binding to the mineralocorticoid receptor.

  2012cites this paper
• Discovery of BAY 94‐8862: A Nonsteroidal Antagonist of the Mineralocorticoid Receptor for the Treatment of Cardiorenal Diseases

  2012cites this paper
• Molecular pharmacology of the mineralocorticoid receptor: prospects for novel therapeutics.

  2012cites this paper
• PRIMARY ALDOSTERONISM IN PREGNANCY

  2012cites this paper
• Review Article Suppression of Aldosterone Synthesis and Secretion by Ca 2+ Channel Antagonists

  2012cites this paper
• [Endocrine disease:progress in diagnosis and treatment. Topics: II. Progress in treatment; 6. Renin-angiotensin-aldosterone inhibition in the medical treatment of primary aldosteronism].

  2012cites this paper
• Therapeutic perspectives in hypertension: novel means for renin–angiotensin–aldosterone system modulation and emerging device-based approaches

  2011influential citation
• Nifedipine, a calcium-channel blocker, attenuated glucose intolerance and white adipose tissue dysfunction in type 2 diabetic KK-A(y) mice.

  2011cites this paper
• Recent Advances in Mineralocorticoid Receptor Antagonists

  2011cites this paper
• Diagnosis and treatment of primary aldosteronism

  2011cites this paper